CRISPR
The Groundbreaking Potential of CRISPR Gene Editing
Olivia Newton-John Cancer Research Institute
PAO-10-24-RTM-09Nov 05, 2024
Gene Editing
MegaBulb DNA: a Non-Viral ssDNA Breakthrough Revolutionizing Gene Editing
Tom Adie, Ph.D.; Elena Stoyanova, Ph.D.
Touchlight
PAO-10-24-CL-01Sep 30, 2024
dbDNA
Revolutionizing the Genetic Medicine Landscape with Enzymatic DNA
Jill Makin
Touchlight
PAO-08-24-CL-01Aug 19, 2024
Cell Therapy
Creating Efficiencies in Engineered Cell Therapy Development with Comprehensive Electroporation Support
Sarah Meeks, Ph.D.
MaxCyte
PAO-09-23-CL-09Sep 28, 2023
Lipid Nanoparticle Development
Lipid Technology for Delivery of Gene-Editing Therapies
Stephen Burgess, Ph.D.
Croda Pharma
PAO-11-022-CL-18Jan 17, 2023
CRISPR Research Innovation
A Cellular Engineering Breakthrough: High-Yield CRISPR Without Viral Vectors
Gladstone Institutes
PR-M08-22-05Aug 25, 2022
CRISPR Clinical Trial
SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
SNIPR BIOME
PR-M04-22-11Apr 20, 2022
Regulatory
FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review
U.S. Food & Drug Administration
PR-M03-22-03Mar 07, 2022
Gene Therapy
Beyond 2020: Looking into the Crystal Ball for Gene Therapy
Ratish Krishnan
MilliporeSigma
PAO-01-21-CL-03Feb 01, 2021
CRISPR RNPs
CRISPR RNPs and the Future of Cell and Gene Therapy
Thomas Lynch, Ph.D.
Aldevron
PAP-Q3-20-CL-002Sep 29, 2020
Synthego Raises $100 Million to Accelerate CRISPR Platform Scale-up in Response to Growing Demand
Synthego
PR-M08-20-NI-43Aug 26, 2020
Gene Editing
Vertex Announces New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies
Vertex
PR-M06-20-NI-017Jun 12, 2020
CRISPR-Cas9
How Close Is CRISPR to Eradicating Disease and Correcting Genetic Defects?
KshitiJ (TJ) Ladage
Nice Insight
PAP-Q1-20-NI-003Mar 19, 2020
CRISPR-Cas9
CRISPR-Cas9 Milestones: The First In Vivo Clinical Trial Is Now Underway
Lydia Michaut
BioAgilytix
PAP-Q4-19-CL-011Dec 06, 2019
Cell and Gene Therapy
CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
Vertex
PR-M11-19-NI-023Nov 20, 2019
CRISPR
Startup Navega Therapeutics Aims to Develop a CRISPR Treatment for Pain
Emilie Branch
Pharma's Almanac
PAO-M09-19-NI-008Sep 04, 2019
Virus
New Insights into Virus Evasion Tactics
Pharma's Almanac
PAO-M00-19-NI-003Sep 04, 2019
CRISPR
Scientists Edit Stem Cell–Derived Neurons Using CRISPR
Pharma's Almanac
PAO-M08-19-NI-039Aug 27, 2019
CRISPR-Cas
Editing Many Sites at Once With CRISPR-Cas
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M08-19-NI-032Aug 27, 2019
CRISPR
Biomaterials Smarten Up With CRISPR
The Wyss Institute for Biologically Inspired Engineering at Harvard University
PR-M08-19-NI-068Aug 23, 2019